COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Melphalan and Busulfan Followed By Donor Peripheral Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00313625
Recruitment Status : Completed
First Posted : April 12, 2006
Last Update Posted : September 21, 2010
National Cancer Institute (NCI)
Information provided by:
Fred Hutchinson Cancer Research Center

Brief Summary:

RATIONALE: Giving chemotherapy, such as melphalan and busulfan, before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving tacrolimus and methotrexate before or after transplant may stop this from happening.

PURPOSE: This phase II trial is studying how well giving melphalan together with busulfan followed by donor peripheral stem cell transplant, tacrolimus, and methotrexate works in treating patients with multiple myeloma.

Condition or disease Intervention/treatment Phase
Multiple Myeloma and Plasma Cell Neoplasm Drug: busulfan Drug: melphalan Drug: methotrexate Drug: tacrolimus Procedure: allogeneic hematopoietic stem cell transplantation Procedure: peripheral blood stem cell transplantation Phase 2

Detailed Description:



  • Evaluate transplant-related mortality in patients with multiple myeloma treated with a myeloablative conditioning regimen comprising melphalan and busulfan followed by HLA-matched, allogeneic peripheral blood stem cell transplantation (PBSCT) and graft-vs-host disease prophylaxis with tacrolimus and methotrexate.


  • Determine the disease response in patients treated with this regimen.
  • Determine the 1-year progression-free survival and overall survival in patients treated with this regimen.


  • Conditioning regimen: Patients receive melphalan IV over 30 minutes on day -6 and busulfan IV over 3 hours on days -5 to -3.
  • Peripheral blood stem cell transplantation (PBSCT): Patients undergo HLA-matched, related donor, allogeneic PBSCT on day 0.
  • Graft-versus-host disease (GVHD) prophylaxis: Patients receive tacrolimus IV continuously or orally twice daily beginning on day -2 and continuing until day 80 followed by a taper until day 180 in the absence of GVHD or disease progression. Patients also receive methotrexate IV on days 1, 3, 6, and 11.

After completion of study treatment, patients are followed every 6 months for 2 years and then annually thereafter.

PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of Intravenous Melphalan and Busulfan Followed by HLA-Matched, Allogeneic Peripheral Blood Stem Cell Transplant for the Treatment of Multiple Myeloma
Study Start Date : September 2005
Actual Primary Completion Date : July 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Multiple Myeloma

Primary Outcome Measures :
  1. Transplant-related mortality at 180 days

Secondary Outcome Measures :
  1. Disease response (complete response)
  2. Progression-free survival
  3. Overall survival at 1 year

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Diagnosis of multiple myeloma

    • Stage I disease with disease progression during the second of ≥ 2 lines of prior therapy
    • Stage II or III disease, meeting 1 of the following criteria:

      • Failed to achieve at least a partial response after ≥ 2 courses of prior therapy
      • Progressive disease after ≥ 2 courses of prior therapy
      • Presented with high-risk features at diagnosis, including any of the following:

        • Cytogenetic abnormality
        • Del 13 or 4,14 by fluorescent in situ hybridization (FISH)
        • Elevated lactic dehydrogenase
        • Beta 2 microglobulin > 5.5
        • Circulating peripheral blood plasma cells
    • Any stage disease with disease progression > 6 months after prior autologous stem cell transplantation
  • Availability of an HLA-matched, related donor between 12 and 75 years of age*

    • No bone marrow donors NOTE: *Donors > 75 years of age are eligible at the discretion of the principal investigator


  • Karnofsky performance status 70-100%
  • Creatinine clearance > 60 mL/min
  • Bilirubin ≤ 2.5 mg/dL
  • ALT/AST < 2 times upper limit of normal
  • Cardiac ejection fraction ≥ 49%
  • DLCO ≥ 50% corrected
  • FEV_1 ≥ 60%
  • Not pregnant or nursing
  • Fertile patients must use effective contraception
  • HIV negative
  • No cirrhosis
  • No chronic inflammatory or fibrotic liver disease


  • See Disease Characteristics
  • At least 6 months since prior autologous transplantation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00313625

Layout table for location information
United States, Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington, United States, 98109-1024
Sponsors and Collaborators
Fred Hutchinson Cancer Research Center
National Cancer Institute (NCI)
Layout table for investigator information
Principal Investigator: William I. Bensinger, MD Fred Hutchinson Cancer Research Center
Layout table for additonal information
Responsible Party: William I. Bensinger, Fred Hutchinson Cancer Research Center Identifier: NCT00313625    
Other Study ID Numbers: 2018.00
CDR0000467231 ( Registry Identifier: PDQ )
First Posted: April 12, 2006    Key Record Dates
Last Update Posted: September 21, 2010
Last Verified: September 2010
Keywords provided by Fred Hutchinson Cancer Research Center:
stage I multiple myeloma
stage II multiple myeloma
stage III multiple myeloma
refractory multiple myeloma
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Abortifacient Agents, Nonsteroidal
Abortifacient Agents
Reproductive Control Agents
Physiological Effects of Drugs
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Dermatologic Agents
Enzyme Inhibitors
Folic Acid Antagonists